viewImugene Ltd

Imugene doses milestone first patient for cancer vaccine trial

The first patient was dosed in the Eastern European country of Moldova.

needle collecting vaccine from jar
The 68 patients will be studied at sites across Asia, Eastern Europe and India

Imugene Ltd (ASX:IMU) has dosed its first patient in its phase II study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

HER-Vaxx is a potentially ground-breaking cancer vaccine designed to produce an antibody response against a cancer growth signal receptor protein called HER-2.

HER-2 is found on the cell surface of multiple cancers including breast and gastric cancers.

READ: Imugene to make further cancer vaccine research presentations at AACR annual meeting

Imugene’s managing director and CEO Leslie Chong said: “There is strong medical investigator interest following the good results seen in the recently completed Phase 1b trial, where 11 out of 14 evaluable patients showed clinically meaningful responses.

“We look forward to providing regular recruitment updates as the Phase 2 study moves toward completion in 2020.”

“The start of the Phase 2 study is an important milestone for Imugene and the many medical professionals seeking treatments for patients with advanced HER-2 positive gastric cancer who often have very few medical options.”

Study being conducted in Asia, Europe and India

The Phase 2 HER-Vaxx study is designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer overexpressing the HER-2 protein.

The study is randomised into two arms of either HER-Vaxx plus standard-of-care chemotherapy or standard-of-care alone.

The primary endpoint is overall survival and secondary endpoint will be progression-free survival. Safety, tolerability and immune response will also be measured.

The Phase 2 trial is being conducted at multiple sites across Asia, Eastern Europe and India.

Patients in these areas have difficulty accessing approved antibody treatments such as Herceptinâ and Perjetaâ marketed by Swiss multinational Roche Holding AG.

There is also a high prevalence of gastric cancer in the countries selected.

Quick facts: Imugene Ltd

Price: 0.1075 AUD

Market: ASX
Market Cap: $509.65 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...


Imugene CEO says PD1-Vaxx could be 'paradigm shift' in oncology

Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong speaks to Proactive's Andrew Scott following the news they've dosed the first patient in a Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, in Melbourne, Australia. The trial is recruiting patients with non-small...

on 1/12/20

2 min read